NOTCH1 and melanoma: In addition, Demcizumab (anti-Notch ligand, DLL4 antibody), OMP-52M51 (anti-Notch1 antibody), and OMP-18R5 (anti-Wnt receptor, FZD monoclonal antibody) are expected to be better therapeutic agents in the future against melanoma (21, 22).